Mark Atwood

1.0k total citations
44 papers, 614 citations indexed

About

Mark Atwood is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Gastroenterology. According to data from OpenAlex, Mark Atwood has authored 44 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Gastroenterology. Recurrent topics in Mark Atwood's work include Pneumonia and Respiratory Infections (25 papers), Respiratory viral infections research (18 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers). Mark Atwood is often cited by papers focused on Pneumonia and Respiratory Infections (25 papers), Respiratory viral infections research (18 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers). Mark Atwood collaborates with scholars based in United States, United Kingdom and Germany. Mark Atwood's co-authors include Derek Weycker, Reiko Sato, Klaus-Uwe Kirchgaessler, John Edelsberg, Michael Kreuter, Justin M. Oldham, Argyrios Tzouvelekis, Philip L. Molyneaux, Toby M. Maher and Joyce Lee and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Mark Atwood

39 papers receiving 603 citations

Peers

Mark Atwood
Eric Knudtson United States
R Taurelle France
Ashutosh Sachdeva United States
Matt S. Zinter United States
Ahmet Ïlvan Türkiye
Heleen J. van Beekhuizen Netherlands
Victoria Price Canada
Laurent Camous France
Nurol Arık Türkiye
Thomas C. Wall United States
Eric Knudtson United States
Mark Atwood
Citations per year, relative to Mark Atwood Mark Atwood (= 1×) peers Eric Knudtson

Countries citing papers authored by Mark Atwood

Since Specialization
Citations

This map shows the geographic impact of Mark Atwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Atwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Atwood more than expected).

Fields of papers citing papers by Mark Atwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Atwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Atwood. The network helps show where Mark Atwood may publish in the future.

Co-authorship network of co-authors of Mark Atwood

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Atwood. A scholar is included among the top collaborators of Mark Atwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Atwood. Mark Atwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atwood, Mark, et al.. (2025). Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Among Adults in the Philippines. Value in Health Regional Issues. 47. 101095–101095.
2.
Rey‐Ares, Lucila, et al.. (2024). Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. Infectious Diseases and Therapy. 13(6). 1235–1251. 3 indexed citations
3.
4.
Kreuter, Michael, Joyce Lee, Argyrios Tzouvelekis, et al.. (2024). Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis. ERJ Open Research. 10(4). 666–2023.
5.
Rozenbaum, Mark H., Raymond Farkouh, Liping Huang, et al.. (2024). Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions. Infectious Diseases and Therapy. 13(4). 745–760. 5 indexed citations
6.
7.
Mignon, A., et al.. (2023). Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Review of Vaccines. 22(1). 1008–1021. 8 indexed citations
8.
Аверин, А. А., et al.. (2023). EE138 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Singaporean Adults Aged ≥18 Years. Value in Health. 26(12). S77–S77. 1 indexed citations
9.
Mendes, Diana, Mark Atwood, Reiko Sato, et al.. (2023). OP78 Cost-effectiveness Of A 20-valent Pneumococcal Conjugate Vaccine To Directly Protect Adults Against Pneumococcal Disease In England. International Journal of Technology Assessment in Health Care. 39(S1). S20–S21.
10.
11.
Kreuter, Michael, Joyce Lee, Argyrios Tzouvelekis, et al.. (2021). Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 204(1). 74–81. 106 indexed citations
12.
Kreuter, Michael, David J. Lederer, María Molina‐Molina, et al.. (2019). Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. CHEST Journal. 156(4). 706–714. 25 indexed citations
13.
14.
Weycker, Derek, Xiaoyan Li, Gail Wygant, et al.. (2018). SAFETY AND EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN THE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM. Journal of the American College of Cardiology. 71(11). A1953–A1953. 1 indexed citations
15.
Cottin, Vincent, David M. Hansell, Nicola Sverzellati, et al.. (2017). Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 196(9). 1162–1171. 57 indexed citations
16.
Delea, Thomas E., Derek Weycker, Mark Atwood, et al.. (2017). Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE. 12(5). e0175721–e0175721. 13 indexed citations
17.
Weycker, Derek, Xiaoyan Li, Mark Atwood, et al.. (2016). Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. Supportive Care in Cancer. 25(2). 439–447. 34 indexed citations
18.
Mangen, Marie‐Josée J., Mark H. Rozenbaum, Susanne M. Huijts, et al.. (2015). Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. European Respiratory Journal. 46(5). 1407–1416. 103 indexed citations
19.
Weycker, Derek, Reiko Sato, David Strutton, et al.. (2012). Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50years. Vaccine. 30(36). 5437–5444. 43 indexed citations
20.
Golini, Don, et al.. (1996). Aspheric Surface Generation Requirements for Magnetorheological Finishing. OF98–OF98. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric Knudtson Breakdown of academic impact, for papers by R Taurelle Breakdown of academic impact, for papers by Ashutosh Sachdeva Breakdown of academic impact, for papers by Matt S. Zinter Breakdown of academic impact, for papers by Ahmet Ïlvan Breakdown of academic impact, for papers by Heleen J. van Beekhuizen Breakdown of academic impact, for papers by Victoria Price Breakdown of academic impact, for papers by Laurent Camous Breakdown of academic impact, for papers by Nurol Arık Breakdown of academic impact, for papers by Thomas C. Wall
Rankless by CCL
2026